Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: Case study

Neuro-Oncology

Volumn 7, Issue 1, 2005, Pages 97-100

  Voloschin, Alfredo D ^a   Louis, David N ^a   Cosgrove, Garth R ^a   Batchelor, Tracy T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LOMUSTINE; PHENYTOIN; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; ARTICLE; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER INFILTRATION; CANCER RECURRENCE; CASE REPORT; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ANALYSIS; CHROMOSOME ARM; CORPUS CALLOSUM; DRUG RESPONSE; FEMALE; FRONTAL LOBE; GENE LOSS; GLIOBLASTOMA; HUMAN; PREOPERATIVE TREATMENT; SEIZURE; SIDE EFFECT; STEREOTAXIC SURGERY; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MAGNETIC RESONANCE IMAGING; NEOADJUVANT THERAPY;

EID: 14644393582     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/S1152851704000560     Document Type: Article

References (17)

1. Cairncross, J.G., and Macdonald, D.R. (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neurol. 23, 360-364.
2. Cairncross, J.G., Ueki, K., Zlatescu, M.C., Lisle, D.K., Finkelstein, D.M., Hammond, R.R., Silver, J.S., Stark, P.C., Macdonald, D.R., Ino, Y., Ramsay, D.A., and Louis, D.N. (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. 90, 1473-1479.
3. Chahlavi, A., Kanner, A., Peereboom, D., Staugaitis, S.M., Elson, P., and Barnett, G. (2003) Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: Preliminary results. J. Neurooncol. 61, 267-273.
4. Deo, S.V., Bhutani, M., Shukla, N.K., Raina, V., Rath, G.K., and Purkayasth, J. (2003) Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0). J. Surg. Oncol. 84, 192-197.
5. Engelhard, H.H., Stelea, A., and Mundt, A. (2003) Oligodendroglioma and anaplastic oligodendroglioma: Clinical features, treatment, and prognosis. Surg. Neurol. 60, 443-456.
6. Glass, J., Hochberg, F.H., Gruber, M.L., Louis, D.N., Smith, D., and Rattner, B. (1992) The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J. Neurosurg. 76, 741-745.
7. Ino, Y., Betensky, R.A., Zlatescu, M.C., Sasaki, H., Macdonald, D.R., Stemmer-Rachamimov, A.O., Ramsay, D.A., Cairncross, J.G., and Louis, D.N. (2001) Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin. Cancer Res. 7, 839-845.
8. Kim, L., Hochberg, F.H., Thornton, A.F., Harsh, G.R., 4th, Patel, H., Finkelstein, D., and Louis, D.N. (1996) Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J. Neurosurg. 85, 602-607.
9. Macdonald, D.R., Gaspar, L.E., and Cairncross, J.G. (1990) Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann. Neurol. 27, 573-574.
10. Reifenberger, G., and Louis, D.N. (2003) Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology. J. Neuropathol. Exp. Neurol. 62, 111-126.
11. Sasaki, H., Zlatescu, M.C., Betensky, R.A., Johnk, L.B., Cutone, A.N., Cairncross, J.G., and Louis, D.N. (2002) Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma." J. Neuropathol. Exp. Neurol. 61, 58-63.
12. Shamberger, R.C., LaQuaglia, M.P., Gebhardt, M.C., Neff, J.R., Tarbell, N.J., Marcus, K.C., Sailer, S.L., Womer, R.B., Miser, J.S., Dickman, P.S., Perlman, E.J., Devidas, M., Linda, S.B., Krailo, M.D., Grier, H.E., and Granowetter, L. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: Impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann. Surg. 238, 563-568.
13. Smith, J.S., Perry, A., Borell, T.J., Lee, H.K., O'Fallon, J., Hosek, S.M., Kimmel, D., Yates, A., Burger, P.C., Scheithauer, B.W., and Jenkins, R.B. (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. 18, 636-645.
14. Valera, E.T., Serafíni, L.N., Machado, H.R., and Tone, L.G. (2003) Complete surgical resection in children with low-grade astrocytomas after neo-adjuvant chemotherapy. Childs Nerv. Syst. 19, 86-90.
15. van den Bent, M.J., Taphoorn, M.J., Brandes, A.A., Menten, J., Stupp, R., Frenay, M., Chinot, O., Kros, J.M., van der Rijt, C.C., Vecht, Ch.J., Allgeier, A., and Gorlia, T. (2003a) Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J. Clin. Oncol. 21, 2525-2528.
16. van den Bent, M., Chinot, O.L., and Cairncross, J.G. (2003b) Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro-Oncol. 5, 128-138.
17. Zlatescu, M.C., Tehrani Yazdi, A., Sasaki, H., Megyesi, J.F., Betensky, R.A., Louis, D.N., and Cairncross, J.G. (2001) Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 61, 6713-6715.